BACKGROUND:Interleukin-1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), and interleukin-6 (IL-6) have been implicated in the cancer anorexia/weight loss syndrome. However, previous smaller studies have yielded conflicting results as to whether circulating, serum concentrations of these cytokines are in fact elevated. As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome. METHODS:Patients with incurable cancer with anorexia and/or weight loss were eligible. All underwent weekly weight measurements and appetite assessment for the first month and then monthly assessments thereafter. Serum was obtained at baseline and at 1 month, and all three cytokines were measured with the Immunolite assay. RESULTS: A total of 118 patients participated. At baseline, 99%, 54%, and 47% of patients' samples had undetectable IL-1beta, TNFalpha, and IL-6, respectively. Similar results were obtained at 1 month. No correlations were observed between serum cytokine concentrations and changes in weight or appetite. Baseline serum IL-6 predicted a diminished survival but only after adjustment for age and cancer site. CONCLUSION:Serum concentrations of IL-1beta, TNFalpha, and IL-6, as measured in this study, provide data of limited clinical value for patients with the cancer anorexia/weight loss syndrome.
RCT Entities:
BACKGROUND:Interleukin-1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), and interleukin-6 (IL-6) have been implicated in the cancer anorexia/weight loss syndrome. However, previous smaller studies have yielded conflicting results as to whether circulating, serum concentrations of these cytokines are in fact elevated. As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome. METHODS:Patients with incurable cancer with anorexia and/or weight loss were eligible. All underwent weekly weight measurements and appetite assessment for the first month and then monthly assessments thereafter. Serum was obtained at baseline and at 1 month, and all three cytokines were measured with the Immunolite assay. RESULTS: A total of 118 patients participated. At baseline, 99%, 54%, and 47% of patients' samples had undetectable IL-1beta, TNFalpha, and IL-6, respectively. Similar results were obtained at 1 month. No correlations were observed between serum cytokine concentrations and changes in weight or appetite. Baseline serum IL-6 predicted a diminished survival but only after adjustment for age and cancer site. CONCLUSION: Serum concentrations of IL-1beta, TNFalpha, and IL-6, as measured in this study, provide data of limited clinical value for patients with the cancer anorexia/weight loss syndrome.
Authors: G Mantovani; A Macciò; L Mura; E Massa; M C Mudu; C Mulas; M R Lusso; C Madeddu; A Dessì Journal: J Mol Med (Berl) Date: 2000 Impact factor: 4.599
Authors: Jesco Pfitzenmaier; Robert Vessella; Celestia S Higano; Jennifer L Noteboom; David Wallace; Eva Corey Journal: Cancer Date: 2003-03-01 Impact factor: 6.860
Authors: Aminah Jatoi; Kendrith Rowland; Charles L Loprinzi; Jeff A Sloan; Shaker R Dakhil; Neil MacDonald; Bruno Gagnon; Paul J Novotny; James A Mailliard; Teresita I L Bushey; Suresh Nair; Brad Christensen Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Lawrence Berk; Jennifer James; Anna Schwartz; Eugen Hug; Anand Mahadevan; Michael Samuels; Lisa Kachnic Journal: Support Care Cancer Date: 2008-02-22 Impact factor: 3.603
Authors: Tara C Mueller; Jeannine Bachmann; Olga Prokopchuk; Helmut Friess; Marc E Martignoni Journal: BMC Cancer Date: 2016-02-08 Impact factor: 4.430